Zyprexa (Olanzapine): Indications, Dosing, and Contraindications
Indications
Zyprexa is FDA-approved for schizophrenia, bipolar I disorder (manic or mixed episodes), agitation associated with schizophrenia/bipolar mania (IM formulation), and in combination with fluoxetine for bipolar depression and treatment-resistant depression 1.
Approved Indications:
- Schizophrenia (adults and adolescents ≥13 years)
- Bipolar I disorder - acute manic or mixed episodes (adults and adolescents ≥13 years)
- Acute agitation - IM formulation for schizophrenia and bipolar mania
- Bipolar depression - when combined with fluoxetine
- Treatment-resistant depression - when combined with fluoxetine
Off-Label Uses:
- Chemotherapy-induced nausea and vomiting (CINV): Olanzapine 5 mg combined with standard antiemetics (5HT3RA, NK1RA, dexamethasone) is highly effective for highly emetogenic chemotherapy, with 79% complete response rates in the delayed phase 2. Guidelines from ASCO and NCCN now recommend this four-drug regimen 3, 4.
Dosing Guidelines
Schizophrenia (Oral):
- Adults: Start 5-10 mg once daily; target dose 10 mg/day; range 5-20 mg/day 1
- Adolescents (13-17 years): Start 2.5-5 mg once daily; target 10 mg/day; maximum 20 mg/day 1
- First-episode psychosis: Use lower initial doses (7.5-10 mg/day) to minimize extrapyramidal side effects and improve adherence 5. Doses above 4-6 mg haloperidol equivalents should be avoided in first-episode patients 5.
Bipolar I Disorder - Acute Mania (Oral):
- Adults: Start 10-15 mg once daily; range 5-20 mg/day 1
- Adolescents: Start 2.5-5 mg once daily; target 10 mg/day 1
Acute Agitation (IM):
- Adults: 10 mg IM (lower doses of 5-7.5 mg for elderly/debilitated); may repeat 5-10 mg after 2 hours and 4 hours (maximum 30 mg/day) 1
- IM olanzapine demonstrates faster onset than haloperidol or lorazepam with favorable EPS profile 6
Bipolar Depression/Treatment-Resistant Depression:
- Olanzapine 5-20 mg combined with fluoxetine 20-50 mg 1
CINV Prophylaxis:
- 5 mg once daily at bedtime on days 1-4 of chemotherapy 2. This dose is sufficient for Japanese patients and reduces sedation compared to 10 mg 7. The 10 mg dose recommended by international guidelines is also tolerated but associated with more somnolence 2.
High-Dose Considerations:
- Doses ≥40 mg/day are used off-label for treatment-resistant cases but are associated with longer hospital stays and increased constipation 8
- Rapid tranquilization with 15-20 mg/day loading doses has been used safely in acute psychosis 9, though this exceeds standard recommendations
Important Dosing Principles
Dose escalation should occur at widely spaced intervals (14-21 days after initial titration) to assess response before increasing 5. Avoid rapid dose escalation that characterized older "rapid neuroleptization" strategies, which increased side effects without improving efficacy 9.
Maximum recommended dose is generally 20 mg/day 1, though higher doses are used off-label in treatment-refractory cases.
Contraindications
The only absolute contraindication listed in the FDA label is hypersensitivity to olanzapine 1.
Black Box Warning:
- Increased mortality in elderly patients with dementia-related psychosis - olanzapine is NOT approved for this population 1
Critical Warnings and Precautions
Metabolic Effects (Most Significant Concern):
- Weight gain, dyslipidemia, and hyperglycemia are substantially more pronounced in adolescents than adults 10
- Monitor fasting glucose, lipid panel, and weight at baseline, 12 weeks, and quarterly 1
- Adolescents experience 27-34% higher drug exposure than adults despite similar pharmacokinetics 10
Other Major Warnings:
- Neuroleptic malignant syndrome (NMS) - discontinue immediately if suspected 1
- Tardive dyskinesia - risk increases with duration; consider discontinuation if signs develop 1
- Orthostatic hypotension - particularly with IM formulation; monitor blood pressure 1, 6
- Leukopenia/neutropenia - monitor CBC in patients with pre-existing low WBC 1
- Seizures - use cautiously in patients with seizure history 1
- Hyperprolactinemia - less elevation than typical antipsychotics but still occurs 11
Common Adverse Effects:
- Sedation/somnolence - dose-dependent; more common with 10 mg vs 5 mg dosing 2
- Dry mouth and constipation - especially at higher doses 7, 8
- Transaminase elevations - usually asymptomatic and mild 11
Special Populations
Pediatric Use:
Olanzapine should be positioned as second-line in adolescents due to substantial metabolic liability, with no clear efficacy advantage over other second-generation antipsychotics 10. When used, employ cautious dosing with stringent metabolic monitoring.
Elderly:
- Use lower starting doses (5 mg)
- Contraindicated in dementia-related psychosis due to increased mortality 1
Hepatic/Renal Impairment:
- Consider lower starting dose (5 mg) in hepatic impairment 1
Clinical Positioning
For first-episode psychosis, olanzapine at 7.5-10 mg/day is appropriate, but atypical antipsychotics with better metabolic profiles may be preferred, especially in adolescents 5, 10. The superior efficacy for negative and depressive symptoms compared to haloperidol 11 must be weighed against metabolic risks.
Long-acting injectable olanzapine is not approved for patients <18 years 10, though LAI formulations remain underutilized despite frequent non-adherence with oral medications 12.
Common Pitfalls:
- Prescribing in elderly dementia patients (contraindicated)
- Inadequate metabolic monitoring, particularly in adolescents
- Rapid dose escalation without adequate trial periods
- Using doses >20 mg/day without clear treatment resistance
- Failing to consider olanzapine 5 mg for CINV prophylaxis in appropriate chemotherapy regimens